After patients developed LM, intrathecal pemetrexed injections were administered in combination with high-dose third-generation EGFR-TKIs, a RET inhibitor, a MET inhibitor, bevacizumab, first- and third-generation EGFR-TKIs, or intravenous chemotherapy. The gene discussed is RET; the disease is lymphangioma.